ReviewCancer immunology, immunotherapy : CII2006
Tumor stroma-associated antigens for anti-cancer immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.Cancer immunology, immunotherapy : CII · 2006Trial
- Functionalized Sulfur-Containing Heterocyclic Analogs Induce Sub-G1 Arrest and Apoptotic Cell Death of Laryngeal Carcinoma In Vitro.Molecules (Basel, Switzerland) · 2023Article
- Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine.International journal of molecular sciences · 2022Review
- Effect of pulsed field ablation on solid tumor cells and microenvironment.Frontiers in oncology · 2022Review
- Review
- Biological Therapies in the Treatment of Cancer-Update and New Directions.International journal of molecular sciences · 2021Review
- Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies - State of the Art.Cancer management and research · 2021Review
- Anti-tumor angiogenesis effect of genetic fusion vaccine encoding murine beta-defensin 2 and tumor endothelial marker-8 in a CT-26 murine colorectal carcinoma model.International journal of clinical and experimental medicine · 2015Article
- Antitumoral materials with regenerative function obtained using a layer-by-layer technique.Drug design, development and therapy · 2015Article
- Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations.The West Indian medical journal · 2014Article
- Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents.Gene therapy · 2013Article
- Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2011Article
- Trends in cancer immunotherapy.Clinical Medicine Insights. Oncology · 2010Article
- Targeting TNF-alpha for cancer therapy.Journal of biology · 2009Article
- Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients.Cancer immunology, immunotherapy : CII · 2009Article
- Anti-cancer therapies targeting the tumor stroma.Cancer immunology, immunotherapy : CII · 2008Review
- Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.Cancer immunology, immunotherapy : CII · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has been widely investigated for its potential use in cancer therapy and it becomes more and more apparent that the selection of target antigens is essential for its efficacy. Indeed, limited clinical efficacy is partly due to immune evasion mechanisms of neoplastic cells, e.g. downregulation of expression or presentation of the respective antigens. Consequently, antigens contributing to tumor cell survival seem to be more suitable therapeutic targets. However, even such antigens may be subject to immune evasion due to impaired processing and cell surface expression. Since development and progression of tumors is not only dependent on cancer cells themselves but also on the active contribution of the stromal cells, e.g. by secreting growth supporting factors, enzymes degrading the extracellular matrix or angiogenic factors, the tumor stroma may also serve as a target for immune intervention. To this end several antigens have been identified which are induced or upregulated on the tumor stroma. Tumor stroma-associated antigens are characterized by an otherwise restricted expression pattern, particularly with respect to differentiated tissues, and they have been successfully targeted by passive and active immunotherapy in preclinical models. Moreover, some of these strategies have already been translated into clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.